ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg Sells 5,873 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 5,873 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $86.53, for a total value of $508,190.69. Following the completion of the transaction, the senior vice president owned 84,024 shares of the company’s stock, valued at approximately $7,270,596.72. The trade was a 6.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

ANI Pharmaceuticals Stock Down 2.8%

Shares of ANIP opened at $87.47 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $90.23. The stock’s 50 day moving average is $67.85 and its two-hundred day moving average is $64.82. The firm has a market cap of $1.90 billion, a P/E ratio of -113.60 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%. The company had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same period last year, the company earned $1.02 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 53.2% compared to the same quarter last year. Analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Truist Financial raised their price objective on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a “hold” rating in a research note on Monday, August 11th. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $93.00 target price (up from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, Guggenheim reaffirmed a “buy” rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday, May 12th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals has a consensus rating of “Buy” and an average price target of $84.75.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ANIP. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the first quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of ANI Pharmaceuticals by 4,636.4% in the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after acquiring an additional 510 shares during the last quarter. National Bank of Canada FI acquired a new stake in shares of ANI Pharmaceuticals in the first quarter worth approximately $79,000. Emerald Advisers LLC boosted its stake in shares of ANI Pharmaceuticals by 414.8% in the second quarter. Emerald Advisers LLC now owns 1,256 shares of the specialty pharmaceutical company’s stock worth $82,000 after acquiring an additional 1,012 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock worth $95,000 after acquiring an additional 881 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.